Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
Andrew Adams(University of Minnesota), Christian P. Larsen(Emory University Hospital), Megan M. Durham(Children’s Institute), Thomas R. Jones(University of New Mexico), Thomas C. Pearson(Emory Healthcare), Norma S. Kenyon(University of Miami), Elizabeth Strobert(Emory University), Dianne Hollenbaugh(Bristol-Myers Squibb (Germany)), Rose Hendrix(Emory Healthcare), Phyllis A. Rees(Emory Healthcare), David Hagerty(Bristol-Myers Squibb (United States)), Robert Townsend(Bristol-Myers Squibb (United States)), Nozomu Shirasugi(Emory University), Karen Price(Purchase College), Shannon Cowan(Emory University)
Cited by 183
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor–Positive Cells and Pathogenesis of Cholestatic Liver Disease
|Gastroenterology|2018|135
Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction
|Bioorganic & Medicinal Chemistry Letters|1995|100
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection
|American Journal of Transplantation|2017|96